Increasing number of cases and deaths caused due to COVID-19 is expected to drive the growth of India dexamethasone market
According to TechSci Research report, “India Dexamethasone Market By Type (Injectables, Capsules, Tablets, Solutions), By Route of Administration (Oral v/s Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders, Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast & Opportunities, FY2026”, the India dexamethasone market is expected to grow at an impressive rate during the forecast period on account of the use for treating various diseases such as arthritis, skin conditions, eye care, respiratory & breathing problems, among others. Additionally, dexamethasone is a corticosteroid hormone which decreases body’s own defensive response and reduces symptoms such as swelling, allergic reactions, among others. This is an off-patent drug which is sold as a generic drug and also under the brand name DexPak, which is cost effective and manufactured by various big and small pharmaceutical companies in the country. Furthermore, the use of drug in high risk patients of COVID-19 is further expected to spur the market growth. However, side effects such as irritability, insomnia, muscle weakness, fluid retention, mood swings, increased appetite, increased blood sugar level, among others might hamper the market growth through FY2026. Also, cytokine over storm while fighting the deadly coronavirus might further restrict the market growth over the next few years.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Dexamethasone Market”
The India dexamethasone market is segmented based on type, route of administration, application, end users, company and region. Based on type, the market can be categorized into injectables, capsules, tablets, and solutions. Here, the tablets segment is expected to dominate the market since they are safe, inexpensive, and safest form of oral medication. Additionally, they have a long shelf life, durable, chewable and can be split. Also, they can accommodate high dose of active ingredient. On the other hand, the capsule segment is expected to witness significant growth in the market since these are tasteless, tamper resistant and break down faster and easily. Further, they have a higher bioavailability and make a large amount of drug enter the bloodstream. Based on route of administration, the market can be split into oral and intravenous. Among these, the oral route is expected to dominate the market on account of its ease, safety, self-administration, prolonged absorption, among others. Additionally, the ease of digestion, efficient patient compliance and ability to accommodate various types of drugs further drive the segmental growth.
Cadila Healthcare Ltd., Wockhardt Ltd., Dwarkesh Pharmaceuticals Private Limited, Schwitz Biotech, Lexine Technochem Private Limited, Mapro Lifescience, Therawin Formulations, Shervotec Pharmaceuticals, Acichem Laboratories, Quality Nexgen Pharmaceuticals Pvt Ltd and others are some of the leading players operating in India dexamethasone market.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4935
Customers can also request for 10% free customization on this report.
“India dexamethasone market is expected to grow at a formidable rate during the forecast period on account of the emergence of the drug as a potential option to treat chronic COVID-19 patients and increasing the survival rate. India has a large number of pharmaceutical companies that are producing the drug at a very affordable rate. However, an increase in the price of API is expected by the drug manufacturers since more than 75% of the API are exported from China but due to the current border tensions with China and also halt in trading activities might lead to an increase in the manufacturing costs during the forecast period. Moreover, the drug has brought a ray of hope to the world for preventing deaths due to COVID-19 and if it gets the approval from FDA it will create lucrative opportunities for the market growth. Also, it will be quite beneficial for Indian pharmaceutical industry since India is one among the major producers of the drug.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“India Dexamethasone Market By Type (Injectables, Capsules, Tablets, Solutions), By Route of Administration (Oral v/s Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders, Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast & Opportunities, FY2026”,has evaluated the future growth potential of India dexamethasone market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India dexamethasone market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017